Targets › HPV18
12 programs from 11 companies in 18 trials: 10 Phase 3, 6 Phase 4, 1 Phase 2, 1 Phase 1; Infectious disease, Oncology, Genitourinary; next expected readout Dec 2026.
Open in Phaseline: the race on HPV18, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Miquel Angel Pavon Ribas | Nonavalent HPV vaccine (9vHPV/Gardasil-9™) Virus-like particles (VLPs) of HPV major capsid L1 protein from 9 HPV types that generate | HPV6, HPV11, HPV16, HPV18, HPV31 | Phase 4 | Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III) | Dec 2026 |
| National Cancer Institute (NCI) | Recombinant Human Papillomavirus Bivalent Vaccine Bivalent HPV vaccine (HPV 16/18 L1 VLP/AS04) | HPV16, HPV18 | Phase 4 | Human Papillomavirus-Related Cervical Carcinoma; Human Papillomavirus Infection | Jan 2027 |
| The University of Texas Medical Branch, Galveston | 9-valent HPV vaccine, 2 doses alternate timing Recombinant human papillomavirus vaccine targeting 9 HPV types | HPV5, HPV6, HPV11, HPV16, HPV18 | Phase 4 | Immunization | Aug 2027 |
| International Agency for Research on Cancer | CERVAVAC quadrivalent HPV vaccine Quadrivalent HPV vaccine targeting HPV types 6, 11, 16, and 18 | HPV6, HPV11, HPV16, HPV18 | Phase 4 | Vaccine Effectiveness | Dec 2028 |
| Erasmus Medical Center | Gardasil 9 Suspension for Injection Nonavalent HPV vaccine targeting HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58 | HPV5, HPV11, HPV16, HPV18 | Phase 4 | Vulvar HSIL | Dec 2028 |
| Merck & Co. (MSD) | 9-valent human papillomavirus (9vHPV) vaccine (Types 6, 11, 16, 18, 31, 33, 45, Aluminum-adjuvanted recombinant protein vaccine containing virus-like particles of recombi | HPV6, HPV11, HPV16, HPV18, HPV31 | Phase 3 | Papillomavirus Infections; Genital Warts | Jan 2027 |
| Shanghai Bovax Biotechnology | 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recom 9-valent HPV recombinant vaccine targeting HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 | HPV6, HPV11, HPV16, HPV18, HPV31 | Phase 3 | Genital Wart; Cervical Cancer | Jul 2027 |
| Xiamen University | Nonavalent HPV vaccine (6,11,16,18,31,33,45,52,58 Type) Recombinant human papillomavirus vaccine targeting 9 HPV types | HPV6, HPV11, HPV16, HPV18, HPV31 | Phase 3 | Cervical Intraepithelial Neoplasia | Dec 2027 |
| Beijing Health Guard Biotechnology | Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (H Recombinant nonavalent HPV vaccine targeting 9 HPV types | HPV6, HPV11, HPV16, HPV18, HPV31 | Phase 3 | Human Papillomavirus Infection | Mar 2028 |
| National Vaccine and Serum Institute, China | Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) Recombinant human papillomavirus vaccine (HPV types 6, 11, 16, 18) | HPV6, HPV11, HPV16, HPV18 | Phase 3 | Human Papillomavirus (HPV) Infection | Jul 2032 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | pBI-11 HPV16/18-targeted therapeutic DNA vaccine | HPV16, HPV18 | Phase 2 | HPV Infection | Nov 2028 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | PVX7 Therapeutic HPV vaccine (pBI-11 DNA + TA-HPV) | HPV16, HPV18 | Phase 1 | Cervical Cancer | Jun 2029 |
Papillomavirus Infections (4) Human Papillomavirus Infection (2) Cervical Cancer (2) Genital Warts (1) Cervical Intraepithelial Neoplasia (1) Immunization (1) HPV Infection (1) Human Papillomavirus-Related Cervical Carcinoma (1) Vulvar HSIL (1) Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III) (1) Genital Wart (1) Vaccine Effectiveness (1)
other (7), mixed (2), small molecule (2), protein or peptide (1)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) Merck & Co. (MSD) (1) Xiamen University (1) The University of Texas Medical Branch, Galveston (1) Beijing Health Guard Biotechnology (1) National Cancer Institute (NCI) (1) Erasmus Medical Center (1) Miquel Angel Pavon Ribas (1) Shanghai Bovax Biotechnology (1) International Agency for Research on Cancer (1) National Vaccine and Serum Institute, China (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.